EP1209152A4 - Derives d'acide omega-amino-alpha-hydroxycarboxylique possedant un antagonisme alpha v beta 3 d'integrine - Google Patents

Derives d'acide omega-amino-alpha-hydroxycarboxylique possedant un antagonisme alpha v beta 3 d'integrine

Info

Publication number
EP1209152A4
EP1209152A4 EP00949959A EP00949959A EP1209152A4 EP 1209152 A4 EP1209152 A4 EP 1209152A4 EP 00949959 A EP00949959 A EP 00949959A EP 00949959 A EP00949959 A EP 00949959A EP 1209152 A4 EP1209152 A4 EP 1209152A4
Authority
EP
European Patent Office
Prior art keywords
alpha
antagonism
omega
beta
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00949959A
Other languages
German (de)
English (en)
Other versions
EP1209152A1 (fr
Inventor
Keiichi Ajito
Naokazu Yahata
Minoru Ishikawa
Dai Kubota
Shoichi Murakami
Mikio Yamamoto
Kazuyuki Fujishima
Shuichi Gomi
Shokichi Ouchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Publication of EP1209152A1 publication Critical patent/EP1209152A1/fr
Publication of EP1209152A4 publication Critical patent/EP1209152A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur des composés de la formule générale (I) qui sont extrêmement solubles dans l'eau et qui possèdent un antagonisme αvβ3 d'intégrine. Dans cette formule, A représente un groupe hétérocyclique constitué de 5 à 7 éléments, éventuellement substitué, contenant 2 atomes d'hydrogène qui peuvent être fusionnés à d'autre noyaux ou -C(-NR?2) (=NR3¿); D représente une liaison, -NR4-, -O- ou -S- ; X et Z représentent chacun CH ou N; R7 et R8 représentent chacun alkyle C¿1-6?, halogéno, oxygène, etc.; Q représente > C=O, > CHR?13¿ ou > CHOR13 ; J représente une liaison ou alkylène C¿1-3?; R?1 à R4, R9 à R11 et R13¿ représentent chacun hydrogène, alkyle, etc.; m est un nombre entier compris entre 0 et 5 ; n est un nombre entier compris entre 0 et 4; et p et q sont chacun un nombre entier compris entre 1 et 3.
EP00949959A 1999-08-05 2000-08-02 Derives d'acide omega-amino-alpha-hydroxycarboxylique possedant un antagonisme alpha v beta 3 d'integrine Withdrawn EP1209152A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP22209899 1999-08-05
JP22209899 1999-08-05
PCT/JP2000/005177 WO2001010844A1 (fr) 1999-08-05 2000-08-02 DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE

Publications (2)

Publication Number Publication Date
EP1209152A1 EP1209152A1 (fr) 2002-05-29
EP1209152A4 true EP1209152A4 (fr) 2003-03-12

Family

ID=16777114

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00949959A Withdrawn EP1209152A4 (fr) 1999-08-05 2000-08-02 Derives d'acide omega-amino-alpha-hydroxycarboxylique possedant un antagonisme alpha v beta 3 d'integrine

Country Status (4)

Country Link
US (1) US6750219B1 (fr)
EP (1) EP1209152A4 (fr)
AU (1) AU6316900A (fr)
WO (1) WO2001010844A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642753B2 (en) 1990-07-24 1993-10-28 Mitsubishi Petrochemical Company Limited Halogen-containing compounds, herbicidal composition containing the same as an active ingredient, and intermediary compounds therefor
JPH0597818A (ja) 1991-10-01 1993-04-20 Mitsubishi Petrochem Co Ltd 新規なピリミジン誘導体およびそれを有効成分とする除草剤
WO1994021599A1 (fr) 1993-03-17 1994-09-29 Meiji Seika Kabushiki Kaisha Nouveau compose a activite inhibitrice de l'agregation des plaquettes
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
EP0910563B1 (fr) 1995-06-29 2003-05-02 Smithkline Beecham Corporation Antagonistes du recepteur de l'integrine
CA2230209A1 (fr) 1995-08-30 1997-03-06 G.D. Searle & Co. Derives de la meta-guanidine, de l'uree, de la thio-uree ou de l'acide aminobenzoique azacyclique utilises comme antagonistes de l'integrine
AU1345697A (en) 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
JP2000502354A (ja) 1995-12-29 2000-02-29 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
ZA9610853B (en) 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.
JP2000516197A (ja) 1996-01-16 2000-12-05 メルク エンド カンパニー インコーポレーテッド インテグリンレセプターアンタゴニスト
EP0888344A1 (fr) 1996-03-15 1999-01-07 The Du Pont Merck Pharmaceutical Company Inhibiteurs de l'integrine spirocycle
DE59706273D1 (de) 1996-03-20 2002-03-21 Hoechst Ag Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
PT891325E (pt) 1996-03-29 2002-07-31 Searle & Co Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina
DE69705300T2 (de) 1996-03-29 2002-05-02 Searle & Co Cyclopropylalkansäurederivate
EP0889876B1 (fr) 1996-03-29 2001-07-25 G.D. SEARLE & CO. Derives meta-substitues du sulphonamide de phenylene
ATE219764T1 (de) 1996-03-29 2002-07-15 Searle & Co Zimtsäurederivate und deren verwendung als integrin-antagonisten
DE69706407T2 (de) 1996-03-29 2002-05-29 Searle & Co META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
WO1997037655A1 (fr) 1996-04-10 1997-10-16 Merck & Co., Inc. ANTAGONISTES DU RECEPTEUR αvβ3
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0934305A4 (fr) 1996-08-29 2001-04-11 Merck & Co Inc Antagonistes de l'integrine
WO1998018460A1 (fr) 1996-10-30 1998-05-07 Merck & Co., Inc. Antagonistes de l'integrine
EP0963370B1 (fr) 1996-12-09 2003-03-19 Eli Lilly And Company Antagonistes de l'integrine
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
JP2001509176A (ja) 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
DE19705450A1 (de) 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
AU6780398A (en) 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
WO1998046220A1 (fr) 1997-04-14 1998-10-22 Merck & Co., Inc. Polytherapie pour la prevention et le traitement de l'osteoporose
GB2327609A (en) 1997-07-23 1999-02-03 Merck & Co Inc A method for eliciting an avß5 or dual avß3/avß5 antagonizing effect
GB2327672A (en) 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
EP1000031A4 (fr) 1997-07-25 2001-08-16 Smithkline Beecham Corp Antagonistes du recepteur de vitronectine
AU2076299A (en) 1998-01-30 1999-08-16 Meiji Seika Kaisha Ltd. Phenylpiperazine derivatives as integrin alphavbeta3 antagonists
JP2003504301A (ja) * 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
ATE542797T1 (de) * 1998-04-09 2012-02-15 Meiji Seika Pharma Co Ltd Aminopiperidinderivate als integrin alpha v beta 3 antagonisten

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO0110844A1 *

Also Published As

Publication number Publication date
EP1209152A1 (fr) 2002-05-29
WO2001010844A1 (fr) 2001-02-15
AU6316900A (en) 2001-03-05
US6750219B1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
CA2424964A1 (fr) Composes azotes a noyau a cinq elements
CA2260999A1 (fr) Composes heterocycliques, leur production et leur utilisation en tant qu'inhibiteurs de tyrosine kinase
CA2286723A1 (fr) Composes tricycliques
WO2001038324A3 (fr) Composes
EP1190710A4 (fr) Principes actifs destines au soin ou a la prevention de diabetes
WO2003059880A1 (fr) Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant
EP1253142A4 (fr) Composes presentant un agonisme vis a vis du recepteur de la thrombopoietine
SG161743A1 (en) Carboxylic acid derivative and salt thereof
DE69405425T2 (de) Oxazolidinedione-Derivate, ihre Herstellung und ihre Verwendung zur Hemmung Zucker und Lipid in Blut
EP1550662A4 (fr) Nouveau compose d'adenine et son application
WO2000047580A3 (fr) Derives de phenyluree et de phenylthiouree
CA2257016A1 (fr) Derives d'imidazolidin-4-one utiles comme agents anticancereux
CA2040517A1 (fr) Derives de 1,8-naphtyridin-2-one
EP1166781A4 (fr) Inhibiteurs de proteasome
EP1201667A4 (fr) Derives de biotine polymerisables, polymere de la biotine et polymere reagissant a la stimulation de l'avidine
EP1057818A4 (fr) DERIVES DE PHENYLPIPERAZINE UTILISES COMME ANTAGONISTES DE L'INTEGRINE ALPHAvBETA3
EP1186604A4 (fr) Derives de benzazepine, procede de preparation de ces derives et utilisation
EP0533951A4 (en) Novel oxazinone derivative
EP1209152A4 (fr) Derives d'acide omega-amino-alpha-hydroxycarboxylique possedant un antagonisme alpha v beta 3 d'integrine
CA2191947A1 (fr) Derives du pyrydyle imidazole et procedes de preparation
WO2003051848A3 (fr) Derives d'acide imidazolidine acetique
EP1174421A4 (fr) Derives de 3-amidinobenzenesulfonamide, compositions medicales qui les contiennent, et produits intermediaires pour leur elaboration
EP1227081A4 (fr) Procede de preparation de derives d'acide oxyminoalcanoique
EP1219619A4 (fr) Derives de piperidine
EP0919554A4 (fr) Derives de quinoxalinedione a substitution imidazole

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20050728